Analysts Set Elanco Animal Health Incorporated (NYSE:ELAN) Price Target at $16.71

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $16.71.

Several brokerages have weighed in on ELAN. The Goldman Sachs Group upped their price target on Elanco Animal Health from $12.50 to $14.00 and gave the stock a “sell” rating in a report on Tuesday, February 27th. Morgan Stanley increased their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. Barclays increased their price objective on Elanco Animal Health from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. Finally, TheStreet upgraded Elanco Animal Health from a “d+” rating to a “c-” rating in a report on Friday, February 23rd.

Elanco Animal Health Price Performance

ELAN opened at $13.53 on Friday. The stock’s 50-day moving average price is $14.96 and its 200 day moving average price is $14.02. Elanco Animal Health has a 12-month low of $7.88 and a 12-month high of $16.88. The company has a current ratio of 2.75, a quick ratio of 1.35 and a debt-to-equity ratio of 0.92. The firm has a market cap of $6.68 billion, a price-to-earnings ratio of -5.41, a PEG ratio of 1.42 and a beta of 1.34.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Monday, February 26th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.02). Elanco Animal Health had a positive return on equity of 6.44% and a negative net margin of 27.87%. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1 billion. During the same period in the previous year, the company posted $0.19 EPS. Elanco Animal Health’s revenue was up 5.1% on a year-over-year basis. As a group, sell-side analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director R David Hoover acquired 20,000 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was acquired at an average cost of $16.14 per share, with a total value of $322,800.00. Following the completion of the acquisition, the director now owns 185,000 shares of the company’s stock, valued at $2,985,900. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 0.57% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Elanco Animal Health

A number of hedge funds and other institutional investors have recently made changes to their positions in ELAN. Jones Financial Companies Lllp acquired a new stake in Elanco Animal Health during the 4th quarter worth approximately $37,000. Tower Research Capital LLC TRC raised its stake in shares of Elanco Animal Health by 169.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,212 shares of the company’s stock worth $93,000 after purchasing an additional 3,906 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Elanco Animal Health during the third quarter worth $95,000. C M Bidwell & Associates Ltd. purchased a new position in Elanco Animal Health in the 3rd quarter valued at $129,000. Finally, Innovis Asset Management LLC acquired a new position in Elanco Animal Health in the 3rd quarter valued at $144,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.